The superiority of IFN-l as a therapeutic candidate to control acute influenza viral lung infection

American Journal of Respiratory Cell and Molecular Biology

Volumn 56, Issue 2, 2017, Pages 202-212

  Kim, Sujin ^a   Kim, Min Ji ^b   Kim, Chang Hoon ^b,c,d   Kang, Ju Wan ^e   Shin, Ha Kyung ^f   Kim, Dong Young ^g   Won, Tae Bin ^g   Han, Doo Hee ^g   Rhee, Chae Seo ^g   Yoon, Joo Heon ^a,b,c,d   Kim, Hyun Jik ^c,g  

^a BK 21 Project for Medical Science   (United States)

^b Research Center for Human Natural Defense System   (United States)

^c Airway Mucus Institute   (United States)

^d Yonsei University College of Medicine   (South Korea)

^e Jeju National University   (South Korea)

^f American School of Paris and Resides in Mareil   (France)

^g Seoul National University College of Medicine   (South Korea)

Author keywords

Acute viral lung infection; IFN l2 3; IFN ; Influenza A virus

Indexed keywords

BETA INTERFERON; GAMMA INTERFERON; INTERLEUKIN 28A; INTERLEUKIN DERIVATIVE; NEUTRALIZING ANTIBODY;

ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HISTOPATHOLOGY; IN VIVO STUDY; INFLUENZA; INNATE IMMUNITY; LUNG INFECTION; MALE; MOUSE; NONHUMAN; UPREGULATION; ACUTE DISEASE; ANIMAL; C57BL MOUSE; DRUG EFFECTS; INTRANASAL DRUG ADMINISTRATION; KINETICS; LUNG; ORTHOMYXOVIRIDAE INFECTIONS; PATHOLOGY; VIROLOGY;

ACUTE DISEASE; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, NEUTRALIZING; IMMUNITY, INNATE; INTERFERON-BETA; INTERLEUKINS; KINETICS; LUNG; MALE; MICE, INBRED C57BL; ORTHOMYXOVIRIDAE INFECTIONS;

EID: 85013055152     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2016-0174OC     Document Type: Article

References (43)

1. Yan N, Chen ZJ. Intrinsic antiviral immunity. Nat Immunol 2012;13: 214-222.
2. Commins SP, Borish L, Steinke JW. Immunologic messenger molecules: cytokines, interferons, and chemokines. J Allergy Clin Immunol 2010; 125:(2 suppl 2):S53-S72.
3. Garćia-Sastre A, Biron CA. Type 1 interferons and the virushost relationship: A lesson in dé tente. Science 2006;312: 879-882.
4. Kawai T, Akira S. Pathogen recognition with Toll-like receptors. Curr Opin Immunol 2005;17:338-344.
5. Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: A complex web of host defenses. Annu Rev Immunol 2014;32: 513-545.
6. Levy DE, Darnell JE Jr. Stats: Transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002;3:651-662.
7. Cheon H, Holvey-Bates EG, Schoggins JW, Forster S, Hertzog P, Imanaka N, Rice CM, Jackson MW, Junk DJ, Stark GR. IFNb-dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage. EMBO J 2013;32: 2751-2763.
8. Wu S, Metcalf JP, Wu W. Innate immune response to influenza virus. Curr Opin Infect Dis 2011;24:235-240.
9. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, Langer JA, Sheikh F, Dickensheets H, Donnelly RP. IFN-ls mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003;4: 69-77.
10. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003;4:63-68.
11. Yao Q, Fischer KP, Arnesen K, Tyrrell DL, Gutfreund KS. Molecular cloning, expression and characterization of Pekin duck interferon-l. Gene 2014;548:29-38.
12. Koltsida O, Hausding M, Stavropoulos A, Koch S, Tzelepis G, Ubel C, Kotenko SV, Sideras P, Lehr HA, Tepe M, et al. IL-28A (IFN-l2) modulates lung DC function to promote Th1 immune skewing and suppress allergic airway disease. EMBO Mol Med 2011;3: 348-361.
13. Sheahan T, Imanaka N, Marukian S, Dorner M, Liu P, Ploss A, Rice CM. Interferon lambda alleles predict innate antiviral immune responses and hepatitis C virus permissiveness. Cell Host Microbe 2014;15: 190-202.
14. Nice TJ, Baldridge MT, McCune BT, Norman JM, Lazear HM, Artyomov M, Diamond MS, Virgin HW. Interferon-l cures persistent murine norovirus infection in the absence of adaptive immunity. Science 2015;347:269-273.
15. Sommereyns C, Paul S, Staeheli P, Michiels T. IFN-lambda (IFN-l) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. Plos Pathog 2008;4:e1000017.
16. Horimoto T, Kawaoka Y. Influenza: lessons from past pandemics, warnings from current incidents. Nat Rev Microbiol 2005;3: 591-600.
17. Haller O, Kochs G, Weber F. The interferon response circuit: induction and suppression by pathogenic viruses. Virology 2006; 344:119-130.
18. Xirakia C, Koltsida O, Stavropoulos A, Thanassopoulou A, Aidinis V, Sideras P, Andreakos E. Toll-like receptor 7-Triggered immune response in the lung mediates acute and long-lasting suppression of experimental asthma. Am J Respir Crit Care Med 2010;181: 1207-1216.
19. Wies E, Wang MK, Maharaj NP, Chen K, Zhou S, Finberg RW, Gack MU. Dephosphorylation of the RNA sensors RIG-I and MDA5 by the phosphatase PP1 is essential for innate immune signaling. Immunity 2013;38:437-449.
20. Slater L, Bartlett NW, Haas JJ, Zhu J, Message SD, Walton RP, Sykes A, Dahdaleh S, Clarke DL, Belvisi MG, et al. Co-ordinated role of TLR3, RIG-I and MDA5 in the innate response to rhinovirus in bronchial epithelium. PLoS Pathog 2010;6: E1001178.
21. Allen IC, Scull MA, Moore CB, Holl EK, McElvania-TeKippe E, Taxman DJ, Guthrie EH, Pickles RJ, Ting JP. The NLRP3 inflammasome mediates in vivo innate immunity to influenza A virus through recognition of viral RNA. Immunity 2009;30: 556-565.
22. Iwasaki A, Pillai PS. Innate immunity to influenza virus infection. Nat Rev Immunol 2014;14:315-328.
23. Pang IK, Iwasaki A. Inflammasomes as mediators of immunity against influenza virus. Trends Immunol 2011;32:34-41.
24. Manicassamy B, Manicassamy S, Belicha-Villanueva A, Pisanelli G, Pulendran B, Garćia-Sastre A. Analysis of in vivo dynamics of influenza virus infection in mice using a GFP reporter virus. Proc Natl Acad Sci USA 2010;107:11531-11536.
25. Perrone LA, Plowden JK, Garćia-Sastre A, Katz JM, Tumpey TM. H5N1 and 1918 pandemic influenza virus infection results in early and excessive infiltration of macrophages and neutrophils in the lungs of mice. Plos Pathog 2008;4:e1000115.
26. Hö gner K, Wolff T, Pleschka S, Plog S, Gruber AD, Kalinke U, Walmrath HD, Bodner J, Gattenlöhner S, Lewe-Schlosser P, et al. Macrophage-expressed IFN-b contributes to apoptotic alveolar epithelial cell injury in severe influenza virus pneumonia. Plos Pathog 2013;9:e1003188.
27. Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev 2004;202:8-32.
28. Kohlmeier JE, Cookenham T, Roberts AD, Miller SC, Woodland DL. Type I interferons regulate cytolytic activity of memory CD81 T cells in the lung airways during respiratory virus challenge. Immunity 2010; 33:96-105.
29. Cakebread JA, Xu Y, Grainge C, Kehagia V, Howarth PH, Holgate ST, Davies DE. Exogenous IFN-b has antiviral and anti-inflammatory properties in primary bronchial epithelial cells from asthmatic subjects exposed to rhinovirus. J Allergy Clin Immunol 2011;127: 1148-54.e9.
30. Wathelet MG, Lin CH, Parekh BS, Ronco LV, Howley PM, Maniatis T. Virus infection induces the assembly of coordinately activated transcription factors on the IFN-b enhancer in vivo. Mol Cell 1998;1:507-518.
31. Onoguchi K, Yoneyama M, Takemura A, Akira S, Taniguchi T, Namiki H, Fujita T. Viral infections activate types I and III interferon genes through a common mechanism. J Biol Chem 2007;282:7576-7581.
32. Osterlund PI, Pietilä TE, Veckman V, Kotenko SV, Julkunen I. IFN regulatory factor family members differentially regulate the expression of type III IFN (IFN-l) genes. J Immunol 2007;179:3434-3442.
33. Kotenko SV. IFN-ls. Curr Opin Immunol 2011;23:583-590.
34. Contoli M, Message SD, Laza-Stanca V, Edwards MR, Wark PA, Bartlett NW, Kebadze T, Mallia P, Stanciu LA, Parker HL, et al. Role of deficient type III interferon-l production in asthma exacerbations. Nat Med 2006;12:1023-1026.
35. Ng CT, Sullivan BM, Teijaro JR, Lee AM, Welch M, Rice S, Sheehan KC, Schreiber RD, Oldstone MB. Blockade of interferon b, but not interferon a, signaling controls persistent viral infection. Cell Host Microbe 2015;17:653-661.
36. Zhou Z, Hamming OJ, Ank N, Paludan SR, Nielsen AL, Hartmann R. Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-Activated protein kinases. J Virol 2007;81:7749-7758.
37. Pott J, Mahlakõiv T, Mordstein M, Duerr CU, Michiels T, Stockinger S, Staeheli P, Hornef MW. IFN-l determines the intestinal epithelial antiviral host defense. Proc Natl Acad Sci USA 2011;108:7944-7949.
38. Jewell NA, Cline T, Mertz SE, Smirnov SV, Flaño E, Schindler C, Grieves JL, Durbin RK, Kotenko SV, Durbin JE. Lambda interferon is the predominant interferon induced by influenza A virus infection in vivo. J Virol 2010;84:11515-11522.
39. Mordstein M, Kochs G, Dumoutier L, Renauld JC, Paludan SR, Klucher K, Staeheli P. Interferon-l contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses. Plos Pathog 2008;4:e1000151.
40. Mordstein M, Neugebauer E, Ditt V, Jessen B, Rieger T, Falcone V, Sorgeloos F, Ehl S, Mayer D, Kochs G, et al. Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J Virol 2010;84:5670-5677.
41. Kim HJ, Kim CH, Ryu JH, Kim MJ, Park CY, Lee JM, Holtzman MJ, Yoon JH. Reactive oxygen species induce antiviral innate immune response through IFN-l regulation in human nasal epithelial cells. Am J Respir Cell Mol Biol 2013;49:855-865.
42. Lasfar A, Abushahba W, Balan M, Cohen-Solal KA. Interferon lambda: A new sword in cancer immunotherapy. Clin Dev Immunol 2011;2011: 349575.
43. Wang J, Oberley-Deegan R, Wang S, Nikrad M, Funk CJ, Hartshorn KL, Mason RJ. Differentiated human alveolar type II cells secrete antiviral IL-29 (IFN-l1) in response to influenza A infection. J Immunol 2009; 182:1296-1304.